Protagonist Therapeutics Inc (PTGX) — Cash Flow Reinvestment Rate

Latest as of March 2025: 0.76x

Protagonist Therapeutics Inc (PTGX) has a Cash Flow Reinvestment Rate of 0.76x as of March 2025, reinvesting $94.95 Million (capex $545.00K plus investments $-94.40 Million) from operating cash flow of $125.36 Million. See how much free cash does Protagonist Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.76x
(Capex + Investments) / Operating CF

Total Reinvested

$94.95 Million
Capex + Investments

Operating Cash Flow

$125.36 Million
USD

Capital Expenditures

$545.00K
USD

Protagonist Therapeutics Inc Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Protagonist Therapeutics Inc across 2 annual periods. For the full cash flow conversion analysis, see PTGX cash generation efficiency.

Annual Cash Flow Reinvestment Rate for Protagonist Therapeutics Inc (2017–2024)

Year-by-year capital reinvestment analysis for Protagonist Therapeutics Inc. See financial flexibility index of Protagonist Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.63x $300.84 Million $184.15 Million $1.35 Million ▼ -61.6%
2017 4.26x $16.49 Million $3.87 Million $666.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow